Apyx Medical Corporation · NASDAQ:APYX
Apyx Medical — Investor Presentation (January 2026)
18 slides from Apyx Medical's investor presentation, January 2026
Slide 1: Investor Presentation: The Leader in Surgical Aesthetics
INVESTOR PRESENTATION THE LEADER IN SURGICAL AESTHETICS January 2026
Slide 2: Cautionary Statements
CAUTIONARY STATEMENTS Forward Looking Statements Certain matters discussed in this presentation and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Fe
Slide 3: The Leader in Surgical Aesthetics
THE LEADER IN SURGICAL AESTHETICS Real Patients, Real Results ▲ Leading developer of surgical technologies used in minimally invasive aesthetic surgical procedures and ▲ Uniquely positioned to address rapid shifts in market following broad adoption of GLP-1 drugs for weight loss ▲ Renuvion® is the o
Slide 4: Market Trends + Macro Signals
MARKET TRENDS + MACRO SIGNALS Apyx is uniquely positioned to lead the surgical aesthetics market and capture the growing post-weight-loss demand Market Trends Procedural Shifts Consumer Behavior • GLP-1 therapies expected to • Liposuction procedures • 72% of GLP-1 users report exceed $100B by 2030 d
Slide 5: Multi Billion Dollar Global Market Opportunity
MULTI BILLION DOLLAR GLOBAL MARKET OPPORTUNITY Generators ~$2.3B1 Generators ~$8.5B3 Market opportunity in U.S. Market opportunity worldwide Handpieces ~$750M2 Handpieces ~$1.9B4 Annual market opportunity in Annual market opportunity U.S. worldwide ~15,000 Total estimated Plastic surgeons, cosmetic
Slide 6: Renuvion Single-Use Handpieces – Recurring Revenue
RENUVION SINGLE-USE HANDPIECES – RECURRING REVENUE Growth Driver over past year >93,000 surgical procedures were completed using Renuvion single-use handpieces in 2024 Single-use handpiece sales account for more than 60% of revenue for the Surgical Aesthetics business segment in 2024 Current handpie
Slide 7: How Renuvion Works
HOW RENUVION Handpiece WORKS inserted sub- dermally Renuvion® utilizes a unique combination of helium plasma and proprietary Contract skin via radiofrequency energy direct heating applied via a single-use wand inserted under the skin. The energy contracts collagen fibers, pulling the skin closer to
Slide 8: Real Results
REAL RESULTS PATIENT 51-YEAR-OLD MALE PROCEDURE TYPE LIPOSUCTION + RENUVION® AMOUNT OF FAT REMOVED 100 ml BEFORE 5.5 MONTHS POST- OP* Photos courtesy of Grant Hamlet, MD. *Patient gained 14 lbs since initial procedure 8
Slide 9: Real Results
REAL RESULTS PATIENT BACK CASE EXAMPLE #1 33-YEAR-OLD FEMALE PROCEDURE TYPE LIPOSUCTION + RENUVION® AMOUNT OF FAT REMOVED 1,750 cc BEFORE 2.5 MONTHS POST- OP Photos courtesy of J Kevin Duplechain, MD. Disclosure: The patient shown in the pictures above is an employee of Apyx Medical. 9
Slide 10: AYON: Revolutionizing Body Contouring
AYON: REVOLUTIONIZING BODY CONTOURING Precise, Superior Results: All-in-One Platform: AYON’s integrated Lipo Intelligent AYON seamlessly integrates Ultrasound- Frequency Tracking (LIFT) Technology™ Assisted Liposuction (UAL), Power Liposuction, offers real-time energy adjustments, Renuvion, infiltra
Slide 11: Driving Patient Demand + Optimizing Provider Results
DRIVING PATIENT DEMAND + OPTIMIZING PROVIDER RESULTS Renuvion DTC & Physician Marketing Strategy AMPLIFY AWARNESS ADRESSING THE PRACTICE GROWTH INFLUENCER THROUGH KEY LOOSE SKIN + ENHANCING MARKETING IMPACT EVENTS EPIDEMIC RESULTS Leveraging partnerships Participating in premier Launching targeted P
Slide 12: Global Presence
GLOBAL PRESENCE Driving Driving growth growth byby expanding expanding customer base and increasing customer base and increasing utilization from existing utilization from existing Sofia, Bulgaria accounts Manufacturing facility accounts We are also registered to sell Weourare also registered produc
Slide 13: Strategic Initiatives Announced in Q4 2024 – Value Creation in 2025
STRATEGIC INITIATIVES ANNOUNCED IN Q4 2024 – VALUE CREATION IN 2025 ▲ Completed a registered direct offering with net proceeds of $7.0 million with a healthcare- focused fund ▲ Amended credit agreement with Perceptive Credit Holdings IV, LP ▲ Significantly reduce the trailing twelve-month Surgical A
Slide 14: 2025 Financial Preliminary Revenue – Revised Upwards
2025 FINANCIAL PRELIMINARY REVENUE – REVISED UPWARDS ▲ Preliminary Fourth Quarter 2025 Revenue Summary: ▲ Total revenue is expected to be in the range of approximately $19.0 to $19.2 million, representing an increase of approximately 34% year-over-year. Operating expenses • Surgical Aesthetics reven
Slide 15: 2025 Company Objectives
2025 COMPANY OBJECTIVES Continue to execute commercial launch of 01 04 AYON in September 2025 and capitalize on Continue to develop network outside of U.S. increased demand for market tailwinds related to GLP-1 drugs 02 05 Continue to expand adoption of Renuvion® Continue to expand library of clinic
Slide 16: Q&A Office Locations
Q&A Office Locations APYX™ MEDICAL CORPORATION 5115 Ulmerton Road • Clearwater, FL 33760-4004 • USA APYX BULGARIA Manufacturing Facility and European Authorized Service Center 16
Slide 17: Compelling Clinical and Real-World Evidence
COMPELLING CLINICAL AND REAL-WORLD EVIDENCE The safety and efficacy of Renuvion is supported by more than 100 published clinical papers, abstracts and posters, as well as 2 multi-site IDE clinical studies. 17 Clinical Publications at: https://physicians.renuvion.com/library/
Slide 18: Beneath the Surface
BENEATH THE SURFACE CUTTING-EDGE 3-IN-1 ENERGY SYSTEM: RENUVION® ENERGY AND FULL MONOPOLAR AND BIPOLAR FUNCTIONALITY INNOVATIVE FEATURES Adaptive home screen CLOUD Intuitive touch screen CONNECTIVITY Presets by area Procedural information ADVANCED recording and reporting GAS SYSTEM Remote system dia